Ameritas Investment Partners Inc. Has $35,000 Position in Nkarta, Inc. (NASDAQ:NKTX)

Ameritas Investment Partners Inc. lessened its position in Nkarta, Inc. (NASDAQ:NKTX) by 33.2% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,106 shares of the company’s stock after selling 550 shares during the period. Ameritas Investment Partners Inc.’s holdings in Nkarta were worth $35,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Citigroup Inc. grew its position in shares of Nkarta by 1,682.8% in the 1st quarter. Citigroup Inc. now owns 76,198 shares of the company’s stock valued at $2,507,000 after buying an additional 71,924 shares during the last quarter. Millennium Management LLC grew its position in shares of Nkarta by 1,796.2% in the 1st quarter. Millennium Management LLC now owns 241,231 shares of the company’s stock valued at $7,936,000 after buying an additional 228,509 shares during the last quarter. Rhumbline Advisers grew its position in shares of Nkarta by 12.2% in the 1st quarter. Rhumbline Advisers now owns 20,870 shares of the company’s stock valued at $687,000 after buying an additional 2,273 shares during the last quarter. Northern Trust Corp grew its position in shares of Nkarta by 4.5% in the 1st quarter. Northern Trust Corp now owns 221,640 shares of the company’s stock valued at $7,292,000 after buying an additional 9,461 shares during the last quarter. Finally, Sectoral Asset Management Inc bought a new stake in shares of Nkarta in the 1st quarter valued at about $5,562,000. 73.30% of the stock is owned by institutional investors and hedge funds.

A number of equities research analysts have commented on NKTX shares. Oppenheimer started coverage on Nkarta in a research report on Thursday, July 15th. They issued an “outperform” rating and a $75.00 price target on the stock. Zacks Investment Research upgraded Nkarta from a “sell” rating to a “hold” rating in a research report on Thursday, August 19th. Cantor Fitzgerald upped their target price on Nkarta from $71.00 to $78.00 and gave the company an “overweight” rating in a research report on Tuesday, June 29th. Finally, Mizuho restated a “buy” rating and set a $81.00 target price on shares of Nkarta in a research report on Wednesday, June 16th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $76.00.

In related news, insider Ralph Brandenberger sold 4,140 shares of the company’s stock in a transaction that occurred on Wednesday, September 1st. The stock was sold at an average price of $32.08, for a total transaction of $132,811.20. Following the transaction, the insider now directly owns 340 shares of the company’s stock, valued at approximately $10,907.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Nadir Mahmood sold 6,500 shares of the stock in a transaction that occurred on Thursday, July 1st. The stock was sold at an average price of $31.71, for a total value of $206,115.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 29,140 shares of company stock worth $937,911. 12.60% of the stock is owned by company insiders.

Shares of Nkarta stock opened at $31.29 on Friday. Nkarta, Inc. has a one year low of $23.02 and a one year high of $79.16. The stock’s 50-day moving average is $32.35 and its 200 day moving average is $32.07. The firm has a market cap of $1.03 billion, a price-to-earnings ratio of -13.97 and a beta of 1.03.

Nkarta (NASDAQ:NKTX) last posted its quarterly earnings results on Thursday, August 12th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.06). On average, analysts predict that Nkarta, Inc. will post -2.69 earnings per share for the current fiscal year.

Nkarta Profile

Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.

Featured Article: Trading Strategy Examples and Plans

Institutional Ownership by Quarter for Nkarta (NASDAQ:NKTX)

Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.